Ad
related to: giant cell arteritis treatment drugs
Search results
Results from the WOW.Com Content Network
Giant cell arteritis (GCA), also called temporal arteritis, is an inflammatory autoimmune disease of large blood vessels. [ 4 ] [ 7 ] Symptoms may include headache , pain over the temples, flu-like symptoms , double vision , and difficulty opening the mouth. [ 3 ]
Tocilizumab, sold under the brand name Actemra among others, is an immunosuppressive drug, used for the treatment of rheumatoid arthritis, systemic juvenile idiopathic arthritis, polyarticular juvenile idiopathic arthritis, giant cell arteritis, cytokine release syndrome, COVID‑19, and systemic sclerosis-associated interstitial lung disease (SSc-ILD).
Arteritis is a vascular disorder characterized by inflammation of the walls of arteries, [1] usually as a result of infection or autoimmune responses. Arteritis, a complex disorder, is still not entirely understood. [2] Arteritis may be distinguished by its different types, based on the organ systems affected by the disease. [2]
People who have polymyalgia rheumatica may also have temporal arteritis (giant cell arteritis), an inflammation of blood vessels in the face which can cause blindness if not treated quickly. [3] The pain and stiffness can result in a lowered quality of life, and can lead to depression. [1]
One small study indicated some beneficial effects of treatment with mavrilimumab compared with those who were not. [7] In April 2021, Kiniksa outlined the next steps for development of Mavrilimumab - including in COVID-19–related acute respiratory distress syndrome (ARDS), giant cell arteritis (GCA), and rheumatoid arthritis (RA).
giant cell arteritis: Pembrolizumab [1] Merck Sharp & Dohme: microsatellite instability-high tumors Ceritinib [1] Novartis Pharmaceuticals: ALK-positive, metastatic non-small cell lung cancer: Dabrafenib [1] Novartis Pharmaceuticals: metastatic non-small cell lung cancer with BRAF V600E mutation Trametinib [1] Novartis Pharmaceuticals
And over the course of the year, we expect two phase 3 readouts in giant cell arteritis and polymyalgia rheumatica which, if positive, would provide further engines for growth for Cosentyx through ...
Treatments are generally directed toward stopping the inflammation and suppressing the immune system. Typically, corticosteroids such as prednisone are used. Additionally, other immune suppression medications, such as cyclophosphamide, are considered. In case of an infection, antimicrobial agents including cephalexin may be prescribed. Affected ...
Ad
related to: giant cell arteritis treatment drugs